C(OC([NH:8][C:9]1[C:17]2[C:12](=[C:13]([F:33])[C:14]([O:30][CH2:31][CH3:32])=[C:15]([NH:18][C:19]([NH:21][CH2:22][C:23]3[CH:28]=[CH:27][CH:26]=[C:25]([F:29])[CH:24]=3)=[O:20])[CH:16]=2)[N:11](C(OC(C)(C)C)=O)[N:10]=1)=O)(C)(C)C.Cl.O1CCOCC1>>[NH2:8][C:9]1[C:17]2[C:12](=[C:13]([F:33])[C:14]([O:30][CH2:31][CH3:32])=[C:15]([NH:18][C:19]([NH:21][CH2:22][C:23]3[CH:28]=[CH:27][CH:26]=[C:25]([F:29])[CH:24]=3)=[O:20])[CH:16]=2)[NH:11][N:10]=14.4 250 mg of tert-butyl 3-tert-butoxycarbonylamino-6-ethoxy-7-fluoro-5-[3-(3-fluorobenzyl)ureido]indazole-1-carboxylate (4.5 mmol) are stirred for 16 hours with 5 ml of HCl/dioxane (4 M). The batch is concentrated and evaporated three times with 20 ml of toluene each time in a rotary evaporator. The residue is purified by column chromatography on silica gel (eluent:ethyl acetate:methanol 9:1). Evaporation of the corresponding fractions gives 50 mg of 1-(3-amino-6-ethoxy-7-fluoro-1H-indazol-5-yl)-3-(3-fluorobenzyl)urea (“A14”) (31%), MS-FAB (M+H+)=362.